FDA's decision to grant a 23andMe Inc. carrier-screening test marketing access opens up new possibilities for the company and for the broader direct-to-consumer genetic test market much sooner than expected.
Not only is the Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome the first direct-to-consumer genetic...